Ibrutinib is the first small-molecule Bruton tyrosine kinase inhibitor approved for treatment of chronic lymphocytic leukemia, initially for relapsed/refractory disease and patients with del 17p, and later also for frontline treatment irrespective of genetic features [1,2,3]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.